EichorEICHOR
Condition: Advanced Squamous Tumors Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Advanced Squamous Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CR
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06509568A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/Phase 2 · 20 location(s) · Hummingbird Bioscience · NCT05910827A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid M
Phase 1 · 2 location(s) · Zelluna Immunotherapy AS · NCT07613723Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC Wi
Phase 3 · 286 location(s) · AstraZeneca · NCT06357533DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07162506ctDNA in Cutaneous Squamous Cell Carcinoma
Phase N/A · 1 location(s) · Massachusetts Eye and Ear Infirmary · NCT06875609Window of Opportunity in Preserving Laryngeal Function Trial
Phase 2 · 1 location(s) · Matthew Spector · NCT07423078Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06793813Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in P
Phase 2 · 8 location(s) · CrystalGenomics, Inc. · NCT05841472Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 11 location(s) · TiumBio Co., Ltd. · NCT05784688A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 47 location(s) · Bristol-Myers Squibb · NCT04895709Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
Phase 2 · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT05069857Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
Phase 2/Phase 3 · 1 location(s) · Shanghai Zhongshan Hospital · NCT04973306QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07463573Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cance
Phase 2 · 1 location(s) · Heath Skinner · NCT05388773A Retrospective Real-World Study Based on RATIONALE-307
Phase N/A · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07478809Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT06718205A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
Phase 3 · 28 location(s) · Mabscale, LLC · NCT05654454A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or
Phase 1/Phase 2 · 1 location(s) · AP Biosciences Inc. · NCT05473156JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Phase 3 · 193 location(s) · Johnson & Johnson Enterprise Innovation Inc. · NCT04892173Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT04099290A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to
Phase 3 · 151 location(s) · mAbxience Research S.L. · NCT06687369SMP-3124LP in Adults With Advanced Solid Tumors
Phase 1/Phase 2 · 11 location(s) · Sumitomo Pharma America, Inc. · NCT06526819Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy f
Phase 3 · 114 location(s) · Federation Francophone de Cancerologie Digestive · NCT06207981TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Phase 3 · 1 location(s) · Fudan University · NCT06676449At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (
Phase 3 · 132 location(s) · Daiichi Sankyo · NCT06644781VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Phase 1/Phase 2 · 15 location(s) · VM Oncology, LLC · NCT03556228Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance C
Phase 3 · 311 location(s) · National Cancer Institute (NCI) · NCT07061977Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT06673693
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.